Review



cd2665  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Tocris cd2665
    Cd2665, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd2665/CD+2665/pm39883086-48-7-15
    Average 93 stars, based on 24 article reviews
    cd2665 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    Control:

    Article Title: 9-cis-retinoic acid signaling in Sertoli cells regulates their immunomodulatory function to control lymphocyte physiology and Treg differentiation
    Article Snippet: .. Next, primary Sertoli cells were treated with 10 − 7 M 9cRA (Sigma-Aldrich, St. Louis, MO, USA), 10 − 6 M CD2665 (Tocris Bioscience, Bristol, UK), 2 × 10 − 6 M Adapalene (Tocris Bioscience, Bristol, UK), 10 − 6 M HX531 (Tocris Bioscience, Bristol, UK), or 10 − 5 M Bexarotene (Tocris Bioscience, Bristol, UK) for 24 h. Control cells were incubated in the presence of the vehicle (0.01% dimethyl sulfoxide). ..

    Article Title: 9-cis-retinoic acid signaling in Sertoli cells regulates their immunomodulatory function to control lymphocyte physiology and Treg differentiation.
    Article Snippet: .. Next, primary Sertoli cells were treated with 10− 7 M 9cRA (Sigma-Aldrich, St. Louis, MO, USA), 10− 6 M CD2665 (Tocris Bioscience, Bristol, UK), 2 × 10− 6 M Adapalene (Tocris Bioscience, Bristol, UK), 10− 6 M HX531 (Tocris Bioscience, Bristol, UK), or 10− 5 M Bexarotene (Tocris Bioscience, Bristol, UK) for 24 h. Control cells were incubated in the presence of the vehicle (0.01% dimethyl sulfoxide). ..

    Incubation:

    Article Title: 9-cis-retinoic acid signaling in Sertoli cells regulates their immunomodulatory function to control lymphocyte physiology and Treg differentiation
    Article Snippet: .. Next, primary Sertoli cells were treated with 10 − 7 M 9cRA (Sigma-Aldrich, St. Louis, MO, USA), 10 − 6 M CD2665 (Tocris Bioscience, Bristol, UK), 2 × 10 − 6 M Adapalene (Tocris Bioscience, Bristol, UK), 10 − 6 M HX531 (Tocris Bioscience, Bristol, UK), or 10 − 5 M Bexarotene (Tocris Bioscience, Bristol, UK) for 24 h. Control cells were incubated in the presence of the vehicle (0.01% dimethyl sulfoxide). ..

    Article Title: 9-cis-retinoic acid signaling in Sertoli cells regulates their immunomodulatory function to control lymphocyte physiology and Treg differentiation.
    Article Snippet: .. Next, primary Sertoli cells were treated with 10− 7 M 9cRA (Sigma-Aldrich, St. Louis, MO, USA), 10− 6 M CD2665 (Tocris Bioscience, Bristol, UK), 2 × 10− 6 M Adapalene (Tocris Bioscience, Bristol, UK), 10− 6 M HX531 (Tocris Bioscience, Bristol, UK), or 10− 5 M Bexarotene (Tocris Bioscience, Bristol, UK) for 24 h. Control cells were incubated in the presence of the vehicle (0.01% dimethyl sulfoxide). ..

    High Performance Liquid Chromatography:

    Article Title: Augmented Therapeutic Potential of EC-Synthetic Retinoids in Caco-2 Cancer Cells Using an In Vitro Approach
    Article Snippet: .. The natural retinoid ATRA, in addition to the synthetic retinoids EC19, EC23, CD437 (RAR-γ selective agonist), AC261066 (RARβ-2 agonist) and CD2665 (Selective RAR-β/γ antagonist), were purchased from Tocris Biosciences (UK; purity ≥ 98% (high-performance liquid chromatography, HPLC)). .. The stock solutions of retinoids were prepared in DMSO (Sigma-Aldrich, St. Louis, MO, USA) to a final concentration of 1 mM and stored at −20 °C.

    Article Title: Augmented Therapeutic Potential of EC-Synthetic Retinoids in Caco-2 Cancer Cells Using an In Vitro Approach.
    Article Snippet: .. The natural retinoid ATRA, in addition to the synthetic retinoids EC19, EC23, CD437 (RAR-γ selective agonist), AC261066 (RARβ-2 agonist) and CD2665 (Selective RAR-β/γ antagonist), were purchased from Tocris Biosciences (UK; purity ≥ 98% (high-performance liquid chromatography, HPLC)). .. The stock solutions of retinoids were prepared in DMSO (Sigma-Aldrich, St. Louis, MO, USA) to a final concentration of 1 mM and stored at −20 ◦C.



    Similar Products

    escc trcs with cd2665  (MedChemExpress)
    92
    MedChemExpress escc trcs with cd2665
    ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of <t>CD2665</t> on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).
    Escc Trcs With Cd2665, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd2665/CD2665/pmc11670471-124-3-6
    Average 92 stars, based on 1 article reviews
    escc trcs with cd2665 - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    cd2665 (rarβ&γ antagonist)  (FUJIFILM)
    90
    FUJIFILM cd2665 (rarβ&γ antagonist)
    ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of <t>CD2665</t> on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).
    Cd2665 (Rarβ&γ Antagonist), supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd2665/cd2665++rar%CE%B2+%CE%B3+antagonist+/pm40288557-43-0-8
    Average 90 stars, based on 1 article reviews
    cd2665 (rarβ&γ antagonist) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cd2665  (Tocris)
    93
    Tocris cd2665
    ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of <t>CD2665</t> on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).
    Cd2665, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd2665/CD+2665/pm39883086-48-7-15
    Average 93 stars, based on 1 article reviews
    cd2665 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    cd2665  (ApexBio)
    90
    ApexBio cd2665
    ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of <t>CD2665</t> on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).
    Cd2665, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd2665/cd2665/pm39938311-222-35-36
    Average 90 stars, based on 1 article reviews
    cd2665 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cas  (MedChemExpress)
    92
    MedChemExpress cas
    ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of <t>CD2665</t> on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).
    Cas, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd2665/CD2665/pm38691454-640-18-93
    Average 92 stars, based on 1 article reviews
    cas - by Bioz Stars, 2026-09
    92/100 stars
    		  Buy from Supplier
    rarγ antagonists cd2665  (Tocris)
    93
    Tocris rarγ antagonists cd2665
    ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of <t>CD2665</t> on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).
    Rarγ Antagonists Cd2665, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd2665/CD+2665/us11833256-356-1-12
    Average 93 stars, based on 1 article reviews
    rarγ antagonists cd2665 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of CD2665 on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).

    Journal: Clinical and Translational Medicine

    Article Title: ZSH‐2208: A novel retinoid with potent anti‐tumour effects on ESCC stem cells via RARγ–TNFAIP3 axis

    doi: 10.1002/ctm2.70148

    Figure Lengend Snippet: ZSH‐2208 inhibits the transcription of TNFAIP3 through reducing the expression of protein of RARγ. (A) Pattern diagram of molecular docking simulation of ZSH‐2208 to RARγ protein. (B–D) Effect of ZSH‐2208 on RARγ protein and gene expression levels in ESCC‐TRCs. (E) Heatmap of the significantly upper (lower)—modulated differentially expressed gene (DEGs) Top50 after ZSH‐2208 treatment. (F) Combined analysis of sequencing by RNA‐seq and ChIP‐seq identified TNFAIP3, a key effector molecule for ZSH‐2208. (G) ZSH‐2208 treatment significantly reduced the binding peak of RARγ protein in the promoter region of TNFAIP3 gene. (H) Three possible binding sites for the RARγ protein on the TNFAIP3 gene promoter. (I) Effect of ZSH‐2208 on TNFAIP3 and TNIP1 at protein level in ESCC‐TRCs. (J) Immunofluorescence staining of TNFAIP3 protein was performed in subcutaneous tumour tissues of nude mice to observe the effect of ZSH‐2208 on TNFAIP3 protein expression. DOX, doxorubicin; red, TNFAIP3: blue. (K–M) Effect of CD2665 on TNFAIP3 and TNIP1 at gene and protein level in ESCC‐TRCs (* p < .05, ** p < .01, *** p < .001, **** p < .0001; ns, not significant).

    Article Snippet: Additionally, we treated ESCC‐TRCs with CD2665 (MCE, HY‐107437, USA), a selective antagonist of RARγ, and observed a reduction in the expression levels of both TNFAIP3 and TNIP1 at the gene level.

    Techniques: Expressing, Gene Expression, Sequencing, RNA Sequencing, ChIP-sequencing, Binding Assay, Immunofluorescence, Staining